Clinical Trial Update: Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant chemoradiation combined with PD-1 antibody SHR-1210 for locally advanced proximal stomach adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN